Sheng Y, Guo Y, Zhao B, Sun M, Dong Y, Yin Y
Commun Biol. 2025; 8(1):425.
PMID: 40082595
PMC: 11906777.
DOI: 10.1038/s42003-025-07854-x.
Keller M, Nakamura M
J Cardiovasc Aging. 2025; 4(26).
PMID: 39958699
PMC: 11827898.
DOI: 10.20517/jca.2024.21.
Gao Y, Yu Y, Zhang M, Yu W, Kang L
Front Oncol. 2024; 14:1448687.
PMID: 39544302
PMC: 11560879.
DOI: 10.3389/fonc.2024.1448687.
Zhang W, Cao X, Wu H, Zhong X, Shi Y, Sun Z
Crit Rev Immunol. 2024; 44(6):111-126.
PMID: 38848298
PMC: 11902286.
DOI: 10.1615/CritRevImmunol.2024051613.
Chen Q, Guo P, Hong Y, Mo P, Yu C
Cell Biosci. 2024; 14(1):41.
PMID: 38553750
PMC: 10979636.
DOI: 10.1186/s13578-024-01222-8.
Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy.
Lu D, Chen J, Qin L, Bijou I, Yi P, Li F
J Med Chem. 2024; 67(7):5333-5350.
PMID: 38551814
PMC: 11105966.
DOI: 10.1021/acs.jmedchem.3c01596.
Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression.
Pimenta R, Malulf F, Romao P, Caetano G, da Silva K, Ghazarian V
J Cancer Res Clin Oncol. 2024; 150(2):70.
PMID: 38305916
PMC: 10837222.
DOI: 10.1007/s00432-023-05598-x.
Critical Roles of SRC-3 in the Development and Progression of Breast Cancer, Rendering It a Prospective Clinical Target.
Varisli L, Dancik G, Tolan V, Vlahopoulos S
Cancers (Basel). 2023; 15(21).
PMID: 37958417
PMC: 10648290.
DOI: 10.3390/cancers15215242.
Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases.
Talukdar P, Chatterji U
Signal Transduct Target Ther. 2023; 8(1):427.
PMID: 37953273
PMC: 10641101.
DOI: 10.1038/s41392-023-01651-w.
Trends in estrogen and progesterone receptors in prostate cancer: a bibliometric analysis.
Liao W, Sui X, Hou G, Yang M, Lin Y, Lu J
Front Oncol. 2023; 13:1111296.
PMID: 37361598
PMC: 10288854.
DOI: 10.3389/fonc.2023.1111296.
HEY1-NCOA2 expression modulates chondrogenic differentiation and induces mesenchymal chondrosarcoma in mice.
Tanaka M, Homme M, Teramura Y, Kumegawa K, Yamazaki Y, Yamashita K
JCI Insight. 2023; 8(10).
PMID: 37212282
PMC: 10322689.
DOI: 10.1172/jci.insight.160279.
Epigenetic differences in NCOA2: a novel biomarker that predicts prognosis in clear cell renal cell carcinoma.
Chen Z, Wang L, Shi J, Xiao W, Yuan C, Meng X
Am J Transl Res. 2023; 15(4):2515-2527.
PMID: 37193192
PMC: 10182516.
The epigenetic function of androgen receptor in prostate cancer progression.
Sawada T, Kanemoto Y, Kurokawa T, Kato S
Front Cell Dev Biol. 2023; 11:1083486.
PMID: 37025180
PMC: 10070878.
DOI: 10.3389/fcell.2023.1083486.
Significant Association of Estrogen Receptor-β Isoforms and Coactivators in Breast Cancer Subtypes.
Choi Y, Pollack S
Curr Issues Mol Biol. 2023; 45(3):2533-2548.
PMID: 36975536
PMC: 10047005.
DOI: 10.3390/cimb45030166.
Preclinical models of prostate cancer - modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo.
Germain L, Lafront C, Paquette V, Neveu B, Paquette J, Pouliot F
Nat Rev Urol. 2023; 20(8):480-493.
PMID: 36788359
DOI: 10.1038/s41585-023-00726-1.
Steroid receptor coactivators - their role in immunity.
Gilad Y, Lonard D, OMalley B
Front Immunol. 2022; 13:1079011.
PMID: 36582250
PMC: 9793089.
DOI: 10.3389/fimmu.2022.1079011.
Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?.
Pozas J, Alvarez Rodriguez S, Albarran Fernandez V, Burgos J, Santoni M, Manneh Kopp R
Cancers (Basel). 2022; 14(24).
PMID: 36551557
PMC: 9776956.
DOI: 10.3390/cancers14246071.
Decidualization of human endometrial stromal cells requires steroid receptor coactivator-3.
Maurya V, Szwarc M, Lonard D, Gibbons W, Wu S, OMalley B
Front Reprod Health. 2022; 4:1033581.
PMID: 36505394
PMC: 9730893.
DOI: 10.3389/frph.2022.1033581.
Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance.
Zhang H, Zhou Y, Xing Z, Sah R, Hu J, Hu H
Int J Mol Sci. 2022; 23(21).
PMID: 36362304
PMC: 9655897.
DOI: 10.3390/ijms232113521.
Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment.
Han S, Sung N, Wang J, OMalley B, Lonard D
Breast Cancer Res. 2022; 24(1):73.
PMID: 36316775
PMC: 9620627.
DOI: 10.1186/s13058-022-01568-2.